Imugene

Imugene is a clinical-stage immuno-oncology company developing a suite of novel immunotherapies designed to activate the immune system in cancer patients to treat and eradicate tumors. Our unique platform technologies are designed to harness the body's immune system to fight tumors, potentially achieving similar or greater efficacy compared to synthetic monoclonal antibodies and other immunotherapies. Our pipeline includes multiple B-cell vaccine immunotherapy candidates and oncolytic virus therapies (CF33), aimed at combining standard-of-care treatments with emerging immunotherapies for various cancers. We are supported by a leadership team of international cancer experts with extensive experience in developing new cancer therapies, many of which have been approved for marketing and sale in global markets.